Vivos Therapeutics (VVOS) Cost of Revenue (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Cost of Revenue for 7 consecutive years, with $2.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 28.65% year-over-year to $2.2 million in Q2 2026; TTM through Jun 2026 was $8.0 million, a 25.54% increase from a year earlier, with the FY2025 full-year figure at $6.9 million, up 14.79% from the prior year.
• Cost of Revenue was $2.2 million for Q2 2026 at Vivos Therapeutics, up from $2.1 million in the prior quarter.
• Over five years, Cost of Revenue peaked at $2.8 million in Q3 2025 and troughed at $836000.0 in Q4 2025.
• A 5-year average of $1.6 million and a median of $1.5 million in 2023 frame the typical range for Cost of Revenue.
• The widest YoY moves for Cost of Revenue: up 86.5% in 2025, down 47.78% in 2025.
• Over 5 years, Cost of Revenue stood at $1.6 million in 2022, then retreated by 25.99% to $1.2 million in 2023, then soared by 38.14% to $1.6 million in 2024, then sank by 47.78% to $836000.0 in 2025, then soared by 163.16% to $2.2 million in 2026.
• The last three Cost of Revenue figures came in at $2.2 million (Q2 2026), $2.1 million (Q1 2026), and $836000.0 (Q4 2025), per Business Quant data.